tobacco use and schizophrenia More than 50% of patients with smoke tobacco. [Fond et al 2017]; [Dickerson et al 2018]; [Oluwoye et al 2019] Despite heavily substantiated nicotine-induced metabolic pharmacokinetic risks, this number refuses This Month in Psychopharmacology
Pay in 4 interest-free payments of $7.29 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
![tobacco use and schizophrenia More than 50% of patients with smoke tobacco. [Fond et al 2017]; [Dickerson et al 2018]; [Oluwoye et al 2019] Despite heavily substantiated nicotine-induced metabolic pharmacokinetic risks, this number refuses This Month in Psychopharmacology](https://www.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/417071/fpsyt-09-00672-HTML/image_m/fpsyt-09-00672-g001.jpg)
![tobacco use and schizophrenia More than 50% of patients with smoke tobacco. [Fond et al 2017]; [Dickerson et al 2018]; [Oluwoye et al 2019] Despite heavily substantiated nicotine-induced metabolic pharmacokinetic risks, this number refuses This Month in Psychopharmacology](https://neurosciencenews.com/files/2019/11/smoking-depression-schizophrenia-neurosciencnews.jpg)




















